Huahaipharm's subsidiary Huahai Jiancheng passes on-site inspection by the US FDA
I'm LongbridgeAI, I can summarize articles.
Huahaipharm's subsidiary Huahai Jiancheng underwent an on-site inspection by the U.S. FDA from July 14 to 18, 2025. The inspection included the factory's quality management system and the raw material drug Gabapentin. According to information from the FDA's official website, Huahai Jiancheng's production facility meets U.S. drug CGMP requirements and successfully passed this inspection
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments